GPCR Valuation

Structure Therapeutics Inc

Add to Watchlist

Advanced Chart

24.450

+0.87(3.690%)1D

Overview
Forecast
Valuation
Earnings

GPCR Relative Valuation

GPCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GPCR is overvalued; if below, it's undervalued.

Historical Valuation

Structure Therapeutics Inc (GPCR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 27.16 is considered Overvalued compared with the five-year average of -35.31. The fair price of Structure Therapeutics Inc (GPCR) is between 2.76 to 20.93 according to relative valuation methord. Compared to the current price of 24.86 USD , Structure Therapeutics Inc is Overvalued By 18.78%.

Relative Value

Fair Zone

2.76-20.93

Current Price：24.86

18.78%

Overvalued

-16.33

Trailing

Forward

-1.99

EV/EBITDA

Structure Therapeutics Inc. (GPCR) has a current EV/EBITDA of -1.99. The 5-year average EV/EBITDA is -3.82. The thresholds are as follows: Strongly Undervalued below -12.17, Undervalued between -12.17 and -7.99, Fairly Valued between 0.36 and -7.99, Overvalued between 0.36 and 4.53, and Strongly Overvalued above 4.53. The current Forward EV/EBITDA of -1.99 falls within the Historic Trend Line -Fairly Valued range.

-1.85

EV/EBIT

Structure Therapeutics Inc. (GPCR) has a current EV/EBIT of -1.85. The 5-year average EV/EBIT is -7.60. The thresholds are as follows: Strongly Undervalued below -17.02, Undervalued between -17.02 and -12.31, Fairly Valued between -2.89 and -12.31, Overvalued between -2.89 and 1.82, and Strongly Overvalued above 1.82. The current Forward EV/EBIT of -1.85 falls within the Overvalued range.

27.16

Structure Therapeutics Inc. (GPCR) has a current PS of 27.16. The 5-year average PS is 5.23. The thresholds are as follows: Strongly Undervalued below -15.11, Undervalued between -15.11 and -4.94, Fairly Valued between 15.40 and -4.94, Overvalued between 15.40 and 25.57, and Strongly Overvalued above 25.57. The current Forward PS of 27.16 falls within the Strongly Overvalued range.

-6.64

P/OCF

Structure Therapeutics Inc. (GPCR) has a current P/OCF of -6.64. The 5-year average P/OCF is -12.88. The thresholds are as follows: Strongly Undervalued below -22.02, Undervalued between -22.02 and -17.45, Fairly Valued between -8.31 and -17.45, Overvalued between -8.31 and -3.74, and Strongly Overvalued above -3.74. The current Forward P/OCF of -6.64 falls within the Overvalued range.

-4.80

P/FCF

Structure Therapeutics Inc. (GPCR) has a current P/FCF of -4.80. The 5-year average P/FCF is -10.77. The thresholds are as follows: Strongly Undervalued below -23.08, Undervalued between -23.08 and -16.92, Fairly Valued between -4.61 and -16.92, Overvalued between -4.61 and 1.54, and Strongly Overvalued above 1.54. The current Forward P/FCF of -4.80 falls within the Historic Trend Line -Fairly Valued range.

Structure Therapeutics Inc (GPCR) has a current Price-to-Book (P/B) ratio of 1.76. Compared to its 3-year average P/B ratio of 3.73 , the current P/B ratio is approximately -52.92% higher. Relative to its 5-year average P/B ratio of 3.73, the current P/B ratio is about -52.92% higher. Structure Therapeutics Inc (GPCR) has a Forward Free Cash Flow (FCF) yield of approximately -12.09%. Compared to its 3-year average FCF yield of -6.40%, the current FCF yield is approximately 88.91% lower. Relative to its 5-year average FCF yield of -6.40% , the current FCF yield is about 88.91% lower.

1.82

P/B

Median3y

3.73

Median5y

3.73

-12.09

FCF Yield

Median3y

-6.40

Median5y

-6.40

Competitors Valuation Multiple

The average P/S ratio for GPCR's competitors is 0.00, providing a benchmark for relative valuation. Structure Therapeutics Inc Corp (GPCR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GPCR.O

Structure Therapeutics Inc

Amylyx Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Performance Decomposition

Market capitalization of GPCR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GPCR in the past 1 year is driven by Unknown.